Literature DB >> 287519

Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids.

R Andreesen, M Modolell, P G Munder.   

Abstract

In order to evaluate the specificity of alkyl-lysophospholipid-induced cell destruction, peripheral blood leukocytes from chronic myelogenous leukemia (CML) patients in chronic phase of the disease as well as in blastic crisis have been separated by density centrifugation. These subpopulations, enriched for the different maturation stages, were tested for their sensitivity to alkyl-lysophospholipids. It is shown that myelocytes in chronic phase CML are resistant, but blast cells from both clinical stages as well as maturational defective myelocytes from blastic crisis CML are highly sensitive to these antimetabolites. In contrast to chronic phase CML myelocytes, these sensitive cells show a high lysophospholipid adsorption rate and lack an O-alkyl-cleavage enzyme.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 287519

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.

Authors:  G W Small; J C Strum; L W Daniel
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

Review 2.  Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane.

Authors:  Kerstin Danker; Werner Reutter; Geo Semini
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Phase I trial of ilmofosine as a 24 hour infusion weekly.

Authors:  M von Mehren; B J Giantonio; C McAleer; R Schilder; J McPhillips; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 4.  Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.

Authors:  E J Meuillet
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Antineoplastic activity of synthetic lysophospholipid analogs.

Authors:  W E Berdel
Journal:  Blut       Date:  1982-02

6.  Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation.

Authors:  W R Vogler; A C Olson; S Okamoto; L B Somberg; L Glasser
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

7.  Response of acute myelomonocytic leukemia to alkyl-lysophospholipids. A case report.

Authors:  W E Berdel; U Fink; P A Maubach; B Permanetter; J Rastetter
Journal:  Blut       Date:  1982-03

8.  Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.

Authors:  I Dulisch; H A Neumann; G W Löhr; R Andreesen
Journal:  Blut       Date:  1985-12

9.  Differential effects of ether lipids on the activity and secretion of interleukin-1 and interleukin-2.

Authors:  R Andreesen; V Giese
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

10.  Cytotoxic activity in the serum of a patient with metastasizing nephroblastoma given intravenous infusions of alkyl-lysophospholipids in a phase I study.

Authors:  R Andreesen; H Arnold; G W Löhr
Journal:  Blut       Date:  1982-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.